132
KORTEJARVI, H, MIKKOLA, J.; BACKMAN, M.; ANTILA, S.; MARVOLA, M.
Development of level A, B and C in vitro-in vivo correlations for modified-release
levosimendan capsules. Int. J. Pharm., v. 241, p.87-95, 2002.
LAKE, O.A.; OLLING, M.; BARENDS, D.M. In vitro/in vivo correlations of dissolution
data of carbamazepine immediate release tablets with pharmacokinetic data obtained
in healthy volunteers. Eur. J. Pharmaceut. Biopharm., v. 48, p.13-19, 1999.
LEVY, G.; LEONARDS, J.; PROCKNAL. J. Development of in vitro dissolution tests
which correlate quantitatively with dissolution rate-limited drug absorption in man. J.
Pharm. Si.,v. 54, nº 12, p. 1719-1722, 1965.
LINDENBERG, M.; KOPP, S. DRESSMAN, J.B. Classification of orally administered
drugs on the World Health organization model list of essential medicines according to
the biopharmaceutics classification system. Eur. J. Pharmaceut. Biopharm., v.58, p.
265-278, 2004.
LÖBENBERG, R.; AMIDON, G.L. Modern bioavailability, bioequivalence and
biopharmaceutics classification system. New scientific approaches to international
regulatory standards. Eur. J. Pharmaceut. Biopharm., v.50, p. 3-12, 2000.
LÖBENBERG, R.; KRÄMER,J; SHAH, V.P.; AMIDON, G.L.; DRESSMAN, J.B.
Dissolution Testing as a Prognostic tool for Oral Drug Absorption: Dissolution
Behavior of Glibenclamide. Pharm. Res., v.17, p. 439-444, 2000.
MANIASSO, N. Ambientes Micelares em Química Analítica. Quim. Nova. V.24, n.1,
p. 87-93, 2001.
MANUAL DE BOAS PRÁTICAS EM BIODISPONIBILIDADE E BIOEQUIVALÊNCIA.
v.1. mod 1: Etapa clínica. Disponível em:
<http://www.anvisa.gov.br/inspecao/bioequivalencia/index.htm> Acesso em: 11 mai.
2005a.